HTA of genetic testing for susceptibility to venous thromboembolism in Italiy

Stefania Boccia, Maria Luisa Di Pietro, Gualtiero Ricciardi, Lamberto Manzoli, Benedetto Simone, S Betti, A Boccia, C Casella, D Coviello, E Di Maria, E Giorgio, M. R. Gualano, G Ivaldi, A Izzotti, C Marzuillo, A Melegaro, A Miani, R Tarricone, A. A. Teleman, V UlianaM Vercelli, P Villari, T. Za

Research output: Working paper


Health Technology Assessment (HTA) is important to address the health policy decisions and to make the translational process possible. HTA is a multidisciplinary method that systematically examines the epidemiological, medical, economic, organizational, social and ethical implications of the application of a health technology – usually a drug, medical device or clinical/surgical procedure. This HTA report aims to assess the current scenario of genetic testing provided for the susceptibility to VTE in Italy. The project is based on the ACCE (Analytic validity, Clinical validity, Clinical utility, Ethical, legal and social aspects) model, which was developed by the National Office of Public Health Genomics, CDC in 2004. By using a comprehensive approach, the report considered all the possible implications related to the utilization of genetic testing for the susceptibility to VTE.
Original languageEnglish
Number of pages72
Publication statusPublished - 2012


  • HTA
  • Italy
  • genetic testing
  • venous thromboembolism


Dive into the research topics of 'HTA of genetic testing for susceptibility to venous thromboembolism in Italiy'. Together they form a unique fingerprint.

Cite this